The Landscape of Signaling Pathways and Proteasome Inhibitors Combinations in Multiple Myeloma.

ABSTRACT: Multiple myeloma is a malignancy of terminally differentiated plasma cells, characterized by an extreme genetic heterogeneity that poses great challenges for its successful treatment. Due to antibody overproduction, MM cells depend on the precise regulation of the protein degradation systems. Despite the success of PIs in MM treatment, resistance and adverse toxic effects such as peripheral neuropathy and cardiotoxicity could arise. To this end, the use of rational combinatorial treatments might allow lowering the dose of inhibitors and therefore, minimize their side-effects. Even though the suppression of different cellular pathways in combination with proteasome inhibitors have shown remarkable anti-myeloma activities in preclinical models, many of these promising combinations often fail

SUBMITTER: Paradzik T 

PROVIDER: S-EPMC8000754 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature